Your browser doesn't support javascript.
loading
Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma.
Arnhold, Viktor; Schmelz, Karin; Proba, Jutta; Winkler, Annika; Wünschel, Jasmin; Toedling, Joern; Deubzer, Hedwig E; Künkele, Annette; Eggert, Angelika; Schulte, Johannes H; Hundsdoerfer, Patrick.
Affiliation
  • Arnhold V; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
  • Schmelz K; Berlin Institute of Health (BIH), Anna-Louisa-Karsch 2, Berlin, Germany.
  • Proba J; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
  • Winkler A; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
  • Wünschel J; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
  • Toedling J; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
  • Deubzer HE; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
  • Künkele A; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
  • Eggert A; Berlin Institute of Health (BIH), Anna-Louisa-Karsch 2, Berlin, Germany.
  • Schulte JH; Neuroblastoma Research Group, Experimental and Clinical Research Center (ECRC), Berlin, Germany.
  • Hundsdoerfer P; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Hematology/Oncology/Stem Cell Transplantation, Berlin, Germany.
Oncotarget ; 9(2): 2304-2319, 2018 Jan 05.
Article in En | MEDLINE | ID: mdl-29416773
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Guideline / Risk_factors_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article Affiliation country: Germany Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Guideline / Risk_factors_studies Language: En Journal: Oncotarget Year: 2018 Document type: Article Affiliation country: Germany Country of publication: United States